Cases

432 F.Supp.2d 408 (2006) ABBOTT LABORATORIES, an Illinois corporation, Fournier Industrie et Sante, a French corporation, and Laboratoires Fournier S.A., a French corporation, Plaintiffs, v. TEVA PHARMACEUTICALS USA, INC., a Delaware Corporation, Defendant. Teva Pharmaceuticals USA, Inc., a Delaware corporation, Teva Pharmaceutical Industries Limited, an Israeli corporation, and Novopharm, Ltd., a Canadian corporation, Counterclaim— Plaintiff

ORDER CHARLES R. BUTLER, JR., Senior District Judge. This matter is before the Court on a motion for summary judgment filed by Defendant Teva Pharmaceuticals USA, Inc. (Doc. 173.) Upon careful consideration of Defendant’s motion and supporting briefs, Plaintiffs’ briefs in opposition and all evidence relevant to the issues raised, the Court finds that Defendant is entitled to summary judgmen

ORDER INGE PRYTZ JOHNSON, SENIOR U.S. DISTRICT JUDGE Pending before the court is defendants Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Ine.’s (“Teva” and “Barr”) motion to dismiss and memorandum in support of said motion (doc. 18) and plaintiffs’ response to said motion (doc. 22). After the defendants’ motion and plaintiffs’ response were filed, defendant Wyeth-Ay-erst Laboratori

AMENDED MEMORANDUM *195AND ORDER1 SARIS, District Judge. I. INTRODUCTION New York City and forty-two New York counties have brought suit against numerous pharmaceutical manufacturers and subsidiaries alleging Medicaid fraud in violation of the federal Best Prices Statute, 42 U.S.C. § 1

On Application for Rehearing BOLIN, Justice. The opinion of January 11, 2013, is withdrawn, and the following is substituted therefor. The United States District Court for the Middle District of Alabama, Southern Division (“the district court”), has certified to this Court the following question pursuant to Rule 18, Ala. RApp. P.: “Under Alabama

MEMORANDUM OPINION AND ORDER W. KEITH WATKINS, Chief Judge. In this pharmaceutical products liability action, Plaintiff Dana Fields alleges that her use of Prozac® during her pregnancy in the mid-1990s caused her son, D.F., to be bom with a congenital heart defect. She brings this action both individually and as the natural parent of D.F., seeking monetary recovery on various state-law claim

685 F.Supp.2d 186 (2010) In re PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE LITIGATION. This Document Relates to: The City of New York, et al., Plaintiffs, v. Abbott Laboratories, et al., Defendants. Civil Action No. 01-12257-PBS. MDL No. 1456. Subcategory Case No. 03-10643-PBS. United States District Court, D. Massachusetts. February 9, 2010.